BioSyent Inc. (RX.V)
| Previous Close | 8.40 |
| Open | 8.44 |
| Bid | 8.34 x 0 |
| Ask | 8.46 x 0 |
| Day's Range | 8.40 - 8.61 |
| 52 Week Range | 7.03 - 9.26 |
| Volume | |
| Avg. Volume | 6,190 |
| Market Cap | 97.521M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | 15.85 |
| EPS (TTM) | 0.53 |
| Earnings Date | May 24, 2024 - May 28, 2024 |
| Forward Dividend & Yield | 0.18 (2.14%) |
| Ex-Dividend Date | Feb 28, 2024 |
| 1y Target Est | 9.00 |
GlobeNewswireBioSyent to Attend Planet MicroCap Showcase
MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th – May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent, will attend a Fireside Q&A session for investors at the conference on Wednesday, May 1st at 2:30pm PDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during th
- GlobeNewswire
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032. “RepaGyn® and Proktis-M® have been part of our product portfolio since
- GlobeNewswire
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Tuesday, April 16 and Wednesday, April 17, 2024. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activi
